Company news
Tonghua Dongbao Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Report for Q3 2026
October 28, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 12th Board of Directors
October 28, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Provision for Asset Impairment
October 28, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 28, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Completion of the Non-trading Transfer of Shares for the Reserved Portion under the R&D and Production System Employee Stock Ownership Plan
October 14, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Completion of the Non-trading Transfer of Shares for the Reserved Portion under the 2025 Employee Stock Ownership Plan
October 13, 2026
Announcement on Satisfaction of Unlocking Conditions for the First Lock-up Period of the Initial Grant under the 2025 Employee Stock Ownership Plan and Expiration of the Lock-up Period
September 29, 2026
(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling Shareholder
September 28, 2026
Announcement on Allocation of Reserved Portion under Employee Stock Ownership Plan for R&D and Production System
August 31, 2026
Announcement on Termination of an R&D Project and Provision for Asset Impairment
August 24, 2026
Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling Shareholder
August 12, 2026
Announcement on Results of Exercising the Preemptive Rights to Subscribe for the Convertible Corporate Bonds Issued to Unspecified Investors by Xiamen Amoytop Biotech Co., Ltd.
August 11, 2026
Announcement on Release of Pledge and Re-pledge of Controlling Shareholder's Shares
July 28, 2026
Announcement on the U.S. Food and Drug Administration Approval for Marketing of Insulin Aspart Injection
July 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
June 17, 2026
Announcement on Release of Pledge and Re-pledge of Controlling Shareholder's Shares
June 15, 2026
Announcement on Resolutions of the 26th Meeting of the 11th Board of Directors
June 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 28, 2026
Announcement on Obtaining Overseas Drug Registration Certificates for Liraglutide Injection
May 25, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Announcement on Convening the 2025 Annual and Q1 2026 Performance Briefing and Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Jilin
May 11, 2026
Announcement on Resolutions of the 25th Meeting of the 11th Board of Directors
April 28, 2026
Announcement on Implementation of Daily Related Transactions in 2025 and Estimated Daily Related Party Transactions in 2026
April 19, 2026
Announcement on Implementation Results of Repurchasing Shares through Call Auction and Share Changes
April 10, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
April 1, 2026
Rectification Report on Decision on Administrative Supervision Measures from Jilin Office of China Securities Regulatory Commission
February 10, 2026
Announcement on Receiving Decision on Administrative Supervision Measures from Jilin Securities Regulatory Bureau
January 30, 2026
Announcement on Expected Increase in Performance for 2025
January 26, 2026
Announcement on Appointment of Senior Management Members
January 15, 2026
Announcement on Changing Signing Engagement Partner and Signatory Certified Public Accountant by Audit Institution
January 8, 2026
Announcement on Resolutions of the 1st Holders' Meeting for Employee Stock Ownership Plan in R&D and Production System
January 7, 2026
Announcement on the Completion of Non-Trade Stock Transfer under the Employee Stock Ownership Plan for R&D and Production System Staff
December 29, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
December 15, 2025
Announcement on Resolutions of the Employee Representative Meeting
November 28, 2025
Announcement on Obtaining Overseas Drug Registration Certificate for Insulin Aspart Injection
November 12, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
November 6, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
November 3, 2025
Announcement on Results of Share Increase by Controlling Shareholder
October 30, 2025
Announcement on Provision for Asset Impairment and Asset Write-off
October 27, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Subject to No Sales Restrictions Concerning Share Repurchase
October 22, 2025
Announcement on Canceling the Board of Supervisors, Amending the "Articles of Association" and Revising and Adding Some Governance Systems
October 17, 2025
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D
October 15, 2025
Announcement on Obtaining of Overseas Marketing Authorization for Insulin Glargine Injection
October 10, 2025
Announcement on the Completion of Non-Trade Stock Transfer under the 2025 Employee Stock Ownership Plan
October 9, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 18, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
September 2, 2025
Announcement on Resolutions of the 16th Meeting of the 11th Board of Directors
August 25, 2025
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D
July 25, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 14, 2025
Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
July 11, 2025